5 Rheumatology Headlines – July 2025
Recent Advances in Respiratory Health: COPD, RSV, and Post-COVID imaging
Table of Contents
recent months have brought significant developments in the understanding and management of respiratory illnesses, from chronic obstructive pulmonary disease (COPD) to the lingering effects of COVID-19 and the impact of respiratory syncytial virus (RSV) in older adults. Hear’s a breakdown of key updates impacting clinical practice.
COPD Management: New Therapies and Expanding Roles for APPs
Chronic Obstructive Pulmonary Disease remains a major public health concern, and recent research is focused on both novel therapies and optimizing care delivery.
Biologics Offer Targeted Treatment for COPD Exacerbations
The FDA approval of mepolizumab for eosinophilic COPD represents a significant step forward. Experts like Joseph Khabbaza, MD, Nikita Desai, MD, and eric Costanzo, MD, emphasize the potential of this biologic to reduce exacerbations and decrease reliance on corticosteroids in a patient population historically challenging to treat. The MATINEE trial data supports this, suggesting a shift towards personalized COPD care, mirroring advancements seen in asthma management. Approximately 40% of COPD patients exhibit type 2 inflammation, making them potential candidates for mepolizumab.
astegolimab’s Mixed Phase 3 Results
Genentech’s (Roche) astegolimab,an IL-33 inhibitor,showed promising but inconsistent results in phase 3 trials for COPD. The ALIENTO trial demonstrated a statistically significant 15.4% reduction in annualized exacerbation rate over 52 weeks. however, the ARNASA trial, despite a similar 14.5% reduction, failed to meet its primary endpoint. While both trials reported no new safety signals, the conflicting efficacy data introduces uncertainty regarding the drug’s regulatory future.
The Expanding Role of advanced Practice Providers (APPs)
Advanced Practice Practitioners (apps) are playing an increasingly vital role in improving COPD care, especially in rural settings. Haley Hoy, PhD, CRNP, highlights their ability to expedite diagnoses, facilitate referrals, and increase access to advanced treatments like endobronchial valve therapy. This is crucial for patients who may otherwise face delays in receiving necessary care. APPs are bridging gaps in access and improving outcomes for COPD patients.
RSV and Cardiovascular Risk in Older Adults
Respiratory Syncytial Virus (RSV) is often considered a childhood illness,but it poses a ample threat to older adults. Recent research reveals a concerning link between RSV hospitalization and increased cardiovascular events.
increased Risk of Heart Failure, AFib, and Mortality
A retrospective cohort study of adults aged 65 and older in Ontario found that 18.5% of those hospitalized with RSV experienced a cardiovascular event within one year – a significantly higher rate than those hospitalized for influenza, urinary tract infections (UTI), or fractures. RSV hospitalizations were specifically associated with elevated risks of heart failure, atrial fibrillation, ICU admission, and prolonged hospital stays. These findings underscore the importance of RSV prevention and prompt treatment in the elderly population.
Post-COVID Imaging: Standardizing Practices for Long-Term Monitoring
The long-term effects of COVID-19 continue to be investigated, and standardized imaging practices are crucial for appropriate patient management.
Consensus Statement for Residual Lung Abnormalities
A new multisociety consensus statement aims to align CT imaging practices for post-COVID-19 residual lung abnormalities. The guidance recommends limiting chest CT scans to patients with persistent symptoms for at least three months post-infection and utilizing low-dose protocols to minimize radiation exposure. Importantly, the consensus statement advocates for using the term ”post-COVID-19 residual lung abnormality” rather of “interstitial lung abnormality” to avoid needless investigations for fibrosis. This standardization will improve diagnostic accuracy and reduce patient anxiety.